Novel Regeneron Deal Puts Partner Decibel In The Driver's Seat
Executive Summary
Regeneron signed a unique agreement with the hearing-focused start-up Decibel in which it will make a minority equity investment and pay R&D costs, but leave full commercialization rights with its partner. The deal sprang from Regeneron’s outreach to venture-backed biotechs.
You may also be interested in...
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.